Oncologists Overtreat Patients at End of Life

Oncology News Central Peer-Spectives

Player FM - Internet Radio Done Right

تمت الإضافة منذ fifty أسبوع

المحتوى المقدم من Jacqueline Stone and Oncololgy News Central. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة Jacqueline Stone and Oncololgy News Central أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.

American Criminal

1
The Menendez Brothers | Five-Year Plan | 1 43:56

منذ 1 year43:56

التشغيل لاحقا

قوائم

إعجاب

احب

43:56

On August 20th, 1989, Lyle and Erik Menendez shot and killed their own parents. Until then, this Beverly Hills family had been a portrait of the American Dream. How did it go so wrong? To listen to all four episodes of 'The Menendez Brothers' right now and ad-free, go to IntoHistory.com . Subscribers enjoy uninterrupted listening, early releases, bonus content and more, only available at IntoHistory.com . If you or someone you know is in crisis, there is free help available at mhanational.org Learn more about your ad choices. Visit megaphone.fm/adchoices…

منذ عام واحد 10:45

MP3•منزل الحلقة

When it comes to end-of-life care for patients with cancer, “I think that there is a real deficit in our training,” says Nathan I. Cherny, MD, director of the Cancer Pain and Palliative Medicine Service at Shaare Zedek Medical Center in Jerusalem, Israel. Dr. Cherney and colleagues recently examined factors contributing to oncologists overtreating patients at the end of life. He discusses key findings and ways to address this continued problem with Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai Cancer Center in Los Angeles. “When one reads practice guidelines, they never include a section of when further treatment is more likely to be harmful than helpful,” Dr. Cherny notes. “Unless it appears in every illness guideline, the message does not necessarily get through that this is something that is really important.”

Dr. Cherny reported serving as a consultant for and owning stock in Canopy Care.

Dr. Figlin reported various financial relationships.

132 حلقات

#Science #Jacqueline Stone #Medical #Cancer #Healthcare #Obroncology #Oncology #Peerspectives #Robertfiglin #Oncololgy News Central #Podcasting Education #OBR

Oncologists Overtreat Patients at End of Life

Oncology News Central Peer-Spectives

published منذ عام واحد

MP3•منزل الحلقة

Dr. Cherny reported serving as a consultant for and owning stock in Canopy Care.

Dr. Figlin reported various financial relationships.

132 حلقات

#Science #Jacqueline Stone #Medical #Cancer #Healthcare #Obroncology #Oncology #Peerspectives #Robertfiglin #Oncololgy News Central #Podcasting Education #OBR

כל הפרקים

1
ASCO President Speaks Out on “Huge Problem” of Oncologist Burnout 14:51

منذ 6 أيام14:51

14:51

Oncologist burnout and career dissatisfaction are a “huge problem,” says Robin T. Zon, MD, president of the American Society of Clinical Oncology (ASCO). Dr. Zon sits down with Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai Cancer Center in Los Angeles, to discuss revelations from a recent ASCO report. “ASCO recognizes that if, in fact, we are going to accomplish our mission, we have to pay very close attention to what is happening to the workforce and the burnout that is associated with that,” Dr. Zon explains. She shares insights into common underlying causes and lays out a plan of attack for improvement. With an emphasis primarily on organizational, and not individual, reforms, Dr. Zon pledges that ASCO will remain focused on burnout and job dissatisfaction. “We are going to continue to have interventions. And we will continue to give voice to our members at all levels.” Dr. Zon reported various financial relationships. Dr. Figlin reported various financial relationships.…

1
Oncologists Overtreat Patients at End of Life 10:45

منذ 5 weeks10:45

10:45

1
FDA Approvals Change Practice for Metastatic Breast Cancer With PIK3CA Mutations 11:01

منذ 11 weeks11:01

11:01

Recent advances in hormone receptor–positive, HER2-negative metastatic breast cancer have led to questions about the timing of genetic testing and the optimal treatment choices for patients. “I, like many others, have changed my personal practice,” says Azka Ali, MD, a medical oncologist at the Cleveland Clinic Taussig Cancer Institute in Ohio. She and Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai Cancer Center in Los Angeles, discuss what newly approved medications for patients with PIK3CA mutations mean for oncologists. “I think the breast cancer landscape is changing faster than we can all keep up with it,” Dr. Ali explains. She breaks down current genetic testing concerns and how she approaches treatment decisions that sometimes take place in a “data-free zone.” Dr. Ali reported no relevant financial disclosures. Dr. Figlin reported various financial relationships.…

1
To Help Oncologists’ Burnout, Should Primary Care Take on More Burden? 11:18

منذ 16 weeks11:18

11:18

The European Society for Medical Oncology (ESMO) Resilience Task Force recently released recommendations intended to reduce burnout in oncology worldwide. One of the task force’s members, Konstantinos Kamposioras, MD, PhD, a consultant in medical oncology at the Christie NHS Foundation Trust in Manchester in the United Kingdom, explains to Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at Cedars-Sinai Cancer Center in Los Angeles, how those recommendations came to be and what institutions should do to help care for cancer care providers. They discuss differences between young oncologists and late-career specialists and consider solutions beyond those laid out in the ESMO guidance. “I’m wondering whether we have not done a good enough job having our primary care colleagues help us manage our cancer cases,” Dr. Figlin speculates. Dr. Kamposioras reported no relevant financial relationships. Dr. Figlin reported various financial relationships.…

1
Choosing Between an “Old Friend” and New Ones in EGFR-Mutated Metastatic NSCLC 12:50

منذ 17 weeks12:50

12:50

When it comes to the treatment of EGFR-mutated metastatic non-small cell lung cancer (NSCLC), osimertinib (Tagrisso) is an “old friend,” says Kamya Sankar, MD, assistant professor and co–medical director of the Thoracic Disease Research Group at Cedars-Sinai Cancer Center in Los Angeles. Recent approvals by the U.S. Food and Drug Administration have introduced several “new friends,” in the form of amivantamab (Rybrevant) and lazertinib (Lazcluze). Dr. Sankar talks with Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology also at Cedars-Sinai Cancer Center, about how to choose among osimertinib monotherapy, osimertinib plus chemotherapy, or amivantamab plus lazertinib. Without overall survival data available for all choices, Dr. Sankar explains how she and her patients decide which treatment is best, as well as how to consider sequential therapy after disease progression. Dr. Sankar reported no relevant financial relationships. Dr. Figlin reported various financial relationships.…

1
rivatization of Cancer Clinical Research Raises Concerns for Practice 13:09

منذ 17 weeks13:09

13:09

“Cancer clinical research has been largely privatized,” explains Joseph Unger, PhD, MS, associate professor in the cancer prevention program at the Fred Hutchinson Cancer Center in Seattle. Dr. Unger and colleagues recently assessed patient enrollment in industry-sponsored and federally sponsored clinical trials. They found an 8:1 ratio favoring participation in research backed by industry. This raises significant concerns, he tells Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai Cancer Center in Los Angeles. Dr. Unger explains what he sees as the root causes for the current imbalance, potential negative effects, and possible solutions for how to “rebalance the portfolio.” “I’m doing whatever I can to help illustrate what the issues are through my research,” he notes. Dr. Unger reported a consulting/advisory role with AstraZeneca and Loxo/Lilly. Dr. Figlin reported various financial relationships.…

1
What 3 Big Trials Mean for Breast Cancer Practice 12:48

منذ 18 weeks12:48

12:48

Treatment approaches for patients with hormone receptor (HR)-positive, HER2-negative breast cancer have rapidly evolved, thanks in part to data from three key studies. Erin Frances Cobain, MD , associate professor at the University of Michigan Rogel Cancer Center in Ann Arbor, explains how findings from the KEYNOTE-756 , monarchE , and NATALEE clinical trials are influencing decision-making for these patients. She and Robert A. Figlin, MD , the Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai Cancer Center in Los Angeles, discuss the evolving role of immunotherapy and how to choose between CDK4/6 inhibitors, given the recent U.S. Food and Drug Administration approval of adjuvant ribociclib for patients with early breast cancer who are at high risk for recurrence. Dr. Cobain acknowledges that these and other findings have led to “challenging discussions,” even if those conversations are ultimately beneficial. Dr. Cobain reported various financial relationships . Dr. Figlin reported various financial relationships .…

1
“Confusing for All of Us”: Questions Arise Over ADCs, HER2 in Metastatic Breast Cancer 14:02

منذ 19 weeks14:02

14:02

Approvals of antibody-drug conjugates (ADCs) for metastatic breast cancer have introduced complex questions about HER2 expression. “It’s certainly been a changing landscape, which has been confusing for all of us,” explains Ian Krop, MD, PhD , director of the clinical trials office, chief clinical research officer, and associate director for clinical sciences at Yale Cancer Center in New Haven, Connecticut. He and Robert A. Figlin, MD , the Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai Cancer Center in Los Angeles, discuss how oncologists should best approach HER2 testing, ADC sequencing, and toxicity concerns. When it comes to answering key questions, “We're a little data-poor in some ways because this is such a rapidly evolving field,” Dr. Krop explains. He also considers what’s next for ADCs in breast cancer, including the potential for those treatments to move into the curative early-disease setting. Dr. Krop reported various financial relationships . Dr. Figlin reported various financial relationships .…

1
"Where Do We Go From Here?" Targeted Therapies Lead to Challenging Choices in Breast Cancer 11:00

منذ 23 weeks11:00

11:00

Newly approved targeted therapies for patients with advanced hormone receptor (HR)-positive, HER2-negative breast cancer are changing care. “We have an abundance of opportunities, but challenges with having to choose the right opportunity at the right time,” says Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai Cancer Center in Los Angeles. Dr. Figlin discusses how to navigate new options with Manali Bhave, MD, a breast medical oncologist and assistant professor at the Emory University School of Medicine in Atlanta. Dr. Bhave stresses that disease progression in breast cancer can’t be addressed with a one-size-fits- all option. “Where do we go from here? I think it is largely dependent on clinical factors, patient comorbidities, and even biomarker status,” she explains. Dr. Bhave and Dr. Figlin discuss recent developments in targeted therapies and important challenges. “We’ve come a long way in treating metastatic HR-positive, HER2-negative breast cancer as more of a chronic disease,” she says. Dr. Bhave reported consulting fees from Lilly, Novartis, and AstraZeneca. Dr. Figlin reported various financial relationships.…

1
After Practice Change in Unresectable Stage III NSCLC, Questions Remain 10:30

منذ 27 weeks10:30

10:30

Data on the use of durvalumab after chemoradiotherapy transformed the standard of care for patients with unresectable stage III non-small cell lung cancer (NSCLC). “This is a real practice-changing observation from the PACIFIC trial,” said Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai Cancer Center in Los Angeles. He recently spoke with Meghan Mooradian, MD, an instructor at Harvard Medical School in Boston, about her team’s recent research assessing the protocol established by the PACIFIC study. “We really are hoping for a cure,” she said in describing how she makes decisions related to the timing of durvalumab after chemoradiotherapy. Dr. Mooradian also addressed toxicity concerns and shared what she sees as lingering questions related to disease progression. “What should we really be using next?” she asked. Dr. Mooradian reported consulting or advisory roles with AstraZeneca, the Bristol Myers Squibb Foundation, Istari Oncology, Regeneron, and Xilio Therapeutics; and other relationships with Aptitude Health, Curio Science, DAVA Oncology, and OncLive/MJH Life Sciences. Dr. Figlin reported various financial relationships.…

1
What "Incredibly Dramatic" Data on Osimertinib in NSCLC Mean for Practice 9:47

منذ 27 weeks9:47

9:47

Results of the phase 3 LAURA clinical trial, presented at the 2024 American Society of Clinical Oncology Annual Meeting, showed that osimertinib significantly improves progression-free survival in patients with unresectable stage III EGFR-mutant non-small cell lung cancer (NSCLC) after chemoradiotherapy. “The benefits of osimertinib in this patient population when compared to placebo are just incredibly dramatic,” noted Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai Cancer Center in Los Angeles. He spoke with lead study author Suresh S. Ramalingam, MD, the Roberto C. Goizueta Distinguished Chair for Cancer Research and the executive director at the Winship Cancer Institute of Emory University in Atlanta, about how oncologists should adjust their practice in the wake of these key findings. Dr. Ramalingam tackled questions about the optimal duration of osimertinib therapy, toxicity concerns, and notable benefits seen in the LAURA data. “Osimertinib reduced both intrathoracic progression and extrathoracic progression, particularly intracranial progression,” he noted. Dr. Ramalingam reported research funding from Amgen, AstraZeneca/MedImmune, Bristol Myers Squibb, Merck, Pfizer, and Takeda; travel, accommodations, and other expenses from AbbVie; and a relationship with the American Cancer Society. Dr. Figlin reported various financial relationships.…

1
“Smart Bombs” Upend Breast Cancer Care: What Oncologists May Not Know About Antibody-Drug Conjugates 10:08

منذ 28 weeks10:08

10:08

“I think the antibody-drug conjugates (ADCs) for physicians, and certainly patients too, are a little bit tough to wrap your head around,” says Erika P. Hamilton, MD, the director of breast cancer and gynecologic cancer research at Sarah Cannon Research Institute in Nashville. She discusses how TROP2-targeting ADCs currently fit into practice with Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai Cancer Center in Los Angeles. From how to “choose the right patient for the right treatment at the right time” to important toxicity concerns, Dr. Hamilton shares her “elevator pitch” to patients when it comes to ADCs. “I think a very easy way to really talk about the activity at this point is just the fact that they’re beating naked chemotherapy. So they are performing better than chemotherapy and, for the most part, comparing favorably in terms of side effects for patients as well.” Dr. Hamilton reported various financial relationships. Dr. Figlin reported various financial relationships.…

1
Oncology Must Do More for Long-Term Cancer Survivors, Expert Says 11:27

منذ 29 weeks11:27

11:27

Various survivorship guidelines for pediatric patients have been established, but “such guidelines do not exist in the adult world,” says Smita Bhatia, MD, MPH, director of the Institute for Cancer Outcomes and Survivorship and the Gay and Bew White Endowed Professor in Pediatric Oncology at the University of Alabama at Birmingham. With the number of adult cancer survivors rapidly rising, the time is now for major oncology societies to help create long-term health recommendations, she tells Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai Cancer Center in Los Angeles. Dr. Bhatia and Dr. Figlin discuss the critical need to explore how recent advances in cancer care, such as targeted treatments and immunotherapies, may affect the future health of survivors. “If we don’t start by constructing large cohorts and following them long term, we will have lost this opportunity that exists right now,” she explains. Dr. Bhatia is an Associate Editor for Journal of Clinical Oncology. Journal policy recused the author from having any role in the peer review of the manuscript discussed. Dr. Figlin reported various financial relationships.…

1
“A Good, Peaceful Death” From Cancer: Oncologists Must Be Part of “National Dialogue” 12:00

منذ 31 weeks12:00

12:00

Obstacles to “achieving a good, peaceful death” prevent many patients with cancer from the “dignified end” that they deserve, says Sunita Puri, MD, a palliative care physician and author. She and Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai Cancer Center in Los Angeles, discuss frustrations and concerns about systemic failures in cancer care when it comes to death and dying. “We need to have this national dialogue around this topic,” argues Dr. Figlin. “It can’t be under the covers, where we don’t talk about it.” Dr. Puri reported no relevant financial disclosures. Dr. Figlin reported various financial relationships.…

1
FDA Approvals in Relapsed/Refractory CLL Set up "Difficult Choice" 9:59

منذ 32 weeks9:59

9:59

When it comes to the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL), "within the last eight months or so, we have had some exciting new events," says Daniel A. Ermann, MD , a hematologist-oncologist and assistant professor at the University of Utah Huntsman Cancer Institute in Salt Lake City. The U.S. Food and Drug Administration approved pirtobrutinib for previously treated CLL in December 2023 and approved the CAR-T therapy lisocabtagene ciloleucel for relapsed/refractory disease in March 2024. These new options for patients with unmet needs present "a difficult choice, and it is a little bit of a balance," Dr. Ermann explains. He discusses key considerations for treatment selection with Robert A. Figlin, MD , the Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai Cancer Center in Los Angeles.…

مرحبًا بك في مشغل أف ام!

يقوم برنامج مشغل أف أم بمسح الويب للحصول على بودكاست عالية الجودة لتستمتع بها الآن. إنه أفضل تطبيق بودكاست ويعمل على أجهزة اندرويد والأيفون والويب. قم بالتسجيل لمزامنة الاشتراكات عبر الأجهزة.

الاستماع إلى +500 موضوع

Amazon eGift Card - Amazon Logo (Animated)

Amazon Basics Clear Thermal Laminating Plastic Paper Laminator Sheets, 9 x 11.5-Inch, 200-Pack, 3mil

Crocs Unisex-Child Classic Clogs, Black/Black, 4 Big Kid

المدونة الصوتية تستحق الاستماع

Oncology News Central Peer-Spectives « » Oncologists Overtreat Patients at End of Life

Oncologists Overtreat Patients at End of Life

المدونة الصوتية تستحق الاستماع

مرحبًا بك في مشغل أف ام!

Goo Gone Original Liquid - 8 Ounce - Surface Safe Adhesive Remover Safely Removes Stickers Labels Decals Residue Tape Chewing Gum Grease Tar Crayon Glue

Bostitch Office Personal Electric Pencil Sharpener, Powerful Stall-Free Motor, High Capacity Shavings Tray, Blue

iBayam 2 Pack Tape Measure Measuring Tape for Body Fabric Sewing Tailor Cloth Knitting Vinyl Home Craft Measurements, 60-Inch Soft Fashion Pink & Retractable Black Double Scales Rulers for Body Weight

SHAPERMINT Shapewear for women - High-Waisted Shapewear Tummy Control Shorts, Faja body shaper, underwear for women

دليل مرجعي سريع

Oncology News Central Peer-Spectives « »
Oncologists Overtreat Patients at End of Life